Alimera Sciences (ALIM) Posts Q4 Loss of 28c/Share

Alimera Sciences (NASDAQ: ALIM) reported Q4 EPS of ($0.28), $0.45 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $1.7 million versus the consensus estimate of $5.11 million.

"This past year was a pivotal year for Alimera Sciences, most notably having received U.S. FDA approval of ILUVIEN in September for the treatment of diabetic macular edema," said Dan Myers, president and chief executive officer of Alimera Sciences. "With the FDA approval process behind us, we have put a strong commercial infrastructure in place to position us to capture market share of the estimated 575,000 clinically significant DME patients in the U.S. in 2015. We have trained and motivated our team of sales managers and representatives, medical liaisons and field and payer reimbursement specialists to educate physicians and patients on the benefits of ILUVIEN. As of December 31, 2014, our U.S. commercial organization included a team of 21, with an additional 32 joining us in the first quarter of 2015."

"In the fourth quarter of 2014, we experienced a decrease in sales in Europe in comparison to the prior quarter. The lower revenue was driven by holiday seasonality that reduced patient office visits, increasing reimbursement challenges in Germany, and the weakening of both the Euro and the British Pound against the U.S. Dollar," continued Mr. Myers. "We did, however, strengthen our balance sheet with a $50 million financing from Deerfield Management. With this added capital, we believe we are well positioned to execute our ILUVIEN commercial launches in the U.S. and in Portugal in the first quarter of 2015 while continuing our marketing and commercialization efforts in the United Kingdom and Germany."

For earnings history and earnings-related data on Alimera Sciences (ALIM) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Kepler Cheuvreux Upgrades Maire Tecnimont (MT:IM) to Buy
• EquipmentShare raises 2026 outlook, approves $500M buyback